Apr 30,2019

Metro Health - University of Michigan Health to Use Glytec’s Software for Inpatient Diabetes Care

Known for high-quality, personalized care and award-winning services, Metro Health – University of Michigan Health is taking inpatient diabetes management to the next level. With a decades-long focus on ensuring glucose control is a top priority, the healthcare organization has selected Glytec’s eGlycemic Management System® (eGMS®) to advance the standardization of best practice. The software-as-a-medical-device eGMS® platform is both patented and FDA cleared.

COLLABORATION PARTNERSHIP

#product & service

View Analyst & Ambassador Comments
Go to original news
Apr 30,2019

Tandem Diabetes Care Announces First Quarter 2019 Financial Results and Updated 2019 Financial Guidance

For the first quarter of 2019, total pump shipments of 14,732 included 5,063 to select geographies outside of the United States. International sales of $11.3 million represent approximately 17 percent of total sales.

View Analyst & Ambassador Comments
Go to original news
Jun 19,2019

Beurer winner of the German Brand Award for the third time

As in previous years, Beurer emerged as the winner in the "Excellent Brands - Health & Pharmaceuticals" class.

View Analyst & Ambassador Comments
Go to original news
Jun 05,2019

Rimidi and Companion Medical Announce First U.S. Partnership to Bring Connected Insulin Data Into the Clinical Workflow

Rimidi, a cloud-based connected care software solution that enables personalized management of chronic cardiometabolic conditions, and Companion Medical, the leader in smart insulin injection delivery, today announced a partnership to enhance data visualization for clinicians treating high-risk patients with diabetes who are on insulin therapy.

COLLABORATION PARTNERSHIP

#connected device

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Jun 10,2019

Lilly study shows Livongo promotes self-efficacy

A study conducted by Livongo and Eli Lilly and Company suggests that the majority of patients enrolled in the Livongo for Diabetes program report high psychosocial self-efficacy or infrequently overwhelmed by their condition after 12 months. More specifically, among a cohort of 957 participants aged an average of 55 years, 61 percent of diabetes patients improved their scores on the Diabetes Empowerment Scale — Short Form (DES-SF) and the Diabetes Distress Scale 2 (DDS2), while 94 percent scored higher on at least one of the validated surveys.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jun 10,2019

Wearable insulin delivery device lowers blood sugar

Valeritas, maker of the V-Go Wearable Insulin Delivery Device, highlighted new data implying that Type 2 diabetes patients who switched to the device from basal insulin regimens could lower their average blood sugar levels. The retrospective analysis included 73 patients, and demonstrated an average A1c reduction of −1.3. Hypoglycemia fell from 23% to 19% among the participants, while severe hypoglycemia was reduced from 10% to 3%.

CLINICAL STUDY

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jun 10,2019

Onduo and Orpyx's expanding partnership

Verily-Sanofi joint venture Onduo and diabetic foot ulcer sensor company Orpyx Medical Technologies extended their collaboration today with the announcement of a new digital diabetes management offering for buyers. Now, companies who are employing the Onduo Virtual Diabetes Clinic — a system of integrated software, devices and services — may choose to expand their programs and provide Orpyx’s sensors to those with diabetes.

COLLABORATION PARTNERSHIP

#product & service

#virtual care

View Analyst & Ambassador Comments
Go to original news
Jun 03,2019

T1D Exchange opens online patient registry for Type 1 treatment, policy research

T1D Exchange, a Boston-based nonprofit that promotes Type 1 diabetes research, has announced the launch of an open online patient data registry. By collecting information from children and adults with the condition, the group hopes to build a substantial longitudinal cohort that will drive new treatment development research and influence new policy or reimbursement decisions.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Jun 07,2019

Senseonics scores coveted non-adjunctive labeling claim for Eversense CGM

Implantable CGM company Senseonics has received approval from the FDA for the non-adjunctive indication for its Eversense device.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 10,2019

Medtronic and Tidepool Sing Partnership for Interoperable Automated Insulin Pump System

On Friday evening, the medical technology company announced a partnership with Tidepool that the pair hope will lead to an interoperable automated insulin pump system. For its part, Medtronic will be developing a Bluetooth-enabled MiniMed pump designed to work with the Tidepool Loop, an open-source iPhone and Apple Watch app that the group hopes to have FDA-cleared for automated insulin delivery. Medtronic will be supporting Tidepool financially, and through the development of an SDK for iPhone-to-pump communication.

COLLABORATION PARTNERSHIP

#product & service

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES